Selenomethionine and Methioninase: Selenium Free Radical Anticancer Activity
Colloidal selenium, was first used to treat cancer as early as 1911 in both humans and mice. Selenium was identified as the toxic component in forage plants of sheep, cattle, and horses in the 1930s. The animal toxicity of selenium compounds was determined to be from the metabolism by animals of the elevated concentrations of Se-methylselenocysteine and selenomethionine in plants. The metabolism of both Se-methylselenocysteine and selenomethionine by animals gives rise to the metabolite, methylselenide (CH3Se-), which if in sufficient concentration oxidizes thiols and generates superoxide and other reactive oxygen species. Cancer cells that may overly express methionine gamma-lyase, or beta-lyase (methioninase), by induced viral genomic expression, are susceptible to free radical-induced apoptosis from selenomethionine or Se-methylselenocysteine supplementation.
Key wordsSelenium Selenide Selenomethionnie Cancer Prevention Therapy
This chapter is dedicated to Edgar N. Drake, PhD (1937–2017). Dr. Ed Drake was Chair and Professor of Chemistry at Angelo State University for many years. As an analytical chemist, he became interested in selenium analyses, and selenium as a chemoprevention dietary supplement. In 2001 he authored a book, “Selenium: Are You Getting Enough to Reduce Your Risk of Cancer?” He was thoroughly versed in selenium biochemistry and one of the early selenium scientists to recognize the pro-oxidant properties of selenium compounds (see Ref. 37). Following retirement, Ed and his wife Nina lived for many years in Estes Park, Colorado, and had a “Million-Dollar View” of Long’s Peak in Rocky Mountain National Park. The author and his wife visited Ed and Nina in Estes Park both in summer and winter, where selenium was always a major conversation topic. He will be missed by the selenium community and the people that knew him.
- 19.Shriver BJ, Praytor LM, Boylan LM et al (2000) Response of growing rats to supplemental selenium in the form of L-Se-methylselenocysteine or L-selenomethionine. FASEB J 14:A513Google Scholar
- 20.Berzelius JJ (1817) Sur deux metaux nouveaux (litium et selenium). Schweigger J 2:1818–1823Google Scholar
- 21.Letter May 6, 1912. In references to a publication to the use of selenium to treat a tongue epithelioma; Le Province Medicale; 13 April 1912 (Paris)Google Scholar
- 22.Sugiura K, Benedict SR (1929) The action of certain dyestuffs on the growth of transplantable tumors. J Cancer Res 13:340 Wasserman A, Keyser FGoogle Scholar
- 42.Hoshiya Y, Guo H, Kubota T et al (1995) Human tumors are methionine dependent in vivo. Anticancer Res 15:717–718Google Scholar
- 46.Tan Y, Xu M, Guo H, Sun X, Kubota T, Hoffman RM (1996) Anticancer efficacy of methioninase in vivo. Anticancer Res 16:3931–3936Google Scholar
- 52.Spallholz JE, Palace VP, Reid TW (2004) Methioninase and selenomethionine but not Se-methylselenocysteine generates methylselenol and superoxide in an in vitro chemiluminescent assay: implications for the nutritional carcinostatic activity of selenoamino acids. Biochem Pharmacol 67:47–554CrossRefGoogle Scholar
- 57.Chen L (1997) Cytotoxicity of antibody-selenium immunoconjugates against erythrocytes and cancer cells. Doctoral Dissertation, Texas Tech UniversityGoogle Scholar
- 59.Reid TW, Grey T, Spallholz JE (2003) A comparison of the ability of se-methylselenocysteine and selenomethionine to kill human prostate cancer cells in vitro. NIH Symposium on Selenium Proteins, Abstract/Poster; Bethesda, MDGoogle Scholar